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Purpose: Gouty arthritis is generally induced by the accumulation of monosodium urate (MSU) crystals in the joints due to elevated
serum uric acid levels, potentially leading to serious pathological disorders such as nephrolithiasis, renal failure, and acute gouty
arthritis. In this study, we aimed to validate the anti-gout effects of carvacrol, a phenolic monoterpene.
Materials and Methods: Male Sprague–Dawley rats were divided into normal saline, disease group by injecting potassium monooxonate (PO) at a dose of 250 mg/kg, and three treatment groups, either with carvacrol 20 mg/kg or 50 mg/kg and 10 mg/kg
allopurinol. The blood and tissue samples were subsequently collected and analyzed using different biochemical and histopathological
techniques.
Results: Our results revealed a significant increase in the serum levels of oxidative stress-related markers, namely, uric acid and
C-reactive protein (CRP), and NLRP3 inflammasome-dependent inflammatory mediators, including nuclear factor kappa B (NF-κB)
and tumor necrosis factor-alpha (TNF-α). Carvacrol administration for seven consecutive days exhibited significant anti-hyperuricemic
and anti-inflammatory effects in a dose-dependent manner. Notably, the 50 mg/kg carvacrol treatment was observed to produce results
similar to the allopurinol treatment. Furthermore, the renal safety of carvacrol was confirmed by the renal function test.
Conclusion: Carvacrol potentially alleviates hyperuricemia-induced oxidative stress and inflammation by regulating the ROS/
NRLP3/NF-κB pathway, thereby exerting protective effects against joint degeneration.
Keywords: hyperuricemia, gout, inflammation, NLRP3, monosodium urate crystals

Introduction
Hyperuricemia is a common biochemical disorder characterized by the increase in serum uric acid levels (up to
7.2 mg/dl) caused by either increased production or a decreased elimination of uric acid from the body.1 The number
of hyperuricemia-related diseases is increasing worldwide, which can be linked to various genetic and environmental
factors, including stressful environments and bad dietary habits.2 It is difficult to estimate the global prevalence of
gout accurately owing to a lack of data for many countries. It is more prevalent in the male population as compared
to females and ranges from a prevalence of <1% to 6.8% and an incidence of 0.58–2.89 per 1000 person-years.3
Another study suggests that 1.4 females and 4 males in every 1000 population are affected by gout annually.4
Hyperuricemia can sometimes lead to different pathological disorders, such as gout, acute gouty arthritis, or chronic
rheumatoid arthritis, an inflammatory autoimmune disease of the joints.5 Since uric acid is a resultant metabolite of
purine oxidation and a purine-rich diet can exacerbate uric acid precipitation. Moreover, a deficiency of the enzyme
hypoxanthine phosphoribosyltransferase (HPRT), a rate-limiting enzyme in purine synthesis, promotes the degradation of purine to uric acid during purine metabolism, leading to medical conditions such as hemolysis and
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rhabdomyolysis.6 When serum uric acid accumulates in the peripheral joints as monosodium urate (MSU) crystals,
the body’s immune response may result in several variants of gout, such as acute gouty arthritis, gouty arthropathy,
uric acid urolithiasis, gouty nephropathy, and nephrolithiasis.7 Furthermore, previous studies found that hyperuricemia is a risk factor for diabetes mellitus, cardiovascular diseases, and chronic renal failure.8–10 Several studies
also established a direct link between hyperuricemia and obesity or hypertension.11,12 However, despite being
common human disorders, gout and hyperuricemia remain poorly managed due to limited therapeutic options that
require both urate-lowering agents and anti-inflammatory drugs.13 Urate level can be reduced using xanthine oxidase
inhibitors (eg, allopurinol and febuxostat), which inhibit urate production, or uricosuric agents (eg, probenecid and
benzbromarone), which promotes urate excretion.14 However, these drugs often induce hypersensitivity reactions,
interact with other drugs, and cause certain disease pathologies, such as renal injury, thereby limiting their wider
application. Furthermore, these medications exert considerable anti-hyperuricemic effects but only have slight antiinflammatory potential. Thus, new anti-inflammatory and urate-lowering agents are being investigated to improve
their efficacy and safety. As a major hallmark of hyperuricemia and gout, combating inflammation is an effective
strategy for prevention and treatment.15 Interestingly, uric acid reportedly exhibits potent antioxidant properties by
executing cellular protection.16 However, several studies reported that urate exacerbates oxidative stress by releasing
free radicals and deactivating innate antioxidant enzymes.17,18 Furthermore, hyperuricemia can trigger inflammation
because MSU crystals are involved in activating the NLRP3 inflammasome and interleukin (IL-1) during the
pathogenesis of acute gout.19,20 Previous studies suggested that the NLRP3 inflammasome is an integral component
of initiating inflammation in gout.21 It is a multimeric protein complex that initiates an inflammatory form of cell
death and triggers the release of pro-inflammatory cytokines IL-1B and IL-18.22 In gout, the cytoplasmic NLRP3
inflammasome composed of procaspase 1 and apoptosis-associated speck-like protein (ASC) is used as a predictor of
inflammation. Recently, several studies utilizing NLRP3 inhibitors in the treatment of gout revealed significantly
favorable results23–25 suggesting that the NLRP3 inflammasome is a potential target protein for gout therapy.
Notably, the release of reactive oxygen species (ROS) and pro-inflammatory mediators, such as IL-1β and tumor
necrosis factor-alpha (TNF-α), often leads to cellular damage and lipid peroxidation (LPO),26 while the simultaneous
inhibition of COX-2 and TNF-α helps alleviate the symptoms of gouty inflammation.27 Furthermore, several studies
demonstrated that suppressing oxidative stress-induced inflammation can effectively ameliorate gout symptoms.
Furthermore, nanoparticles strategies are adopted to ameliorate oxidative stress in gouty pathology.28,29 Still, the
management of hyperuricemia and gout disorders is currently a challenging task and since inflammation is an
integral etiological component underlying gout pathogenesis, and therefore it must be considered during the
development of treatment strategies.
Natural drug repositories are generally a rich source for new drug development. This fact is acknowledged not only
by other researchers but also by our group.30–32 For example, the phenolic monoterpene carvacrol possesses distinct
pharmacological properties, including antioxidant, anti-inflammatory, hepatoprotective, spasmolytic, and anti-cancer
activities.33,34 Furthermore, carvacrol exerts anti-obesity effects, positively regulates cholesterol metabolism, and negatively modulates inflammatory cytokines via numerous pathways.35 Taking into consideration the pharmacological value
of carvacrol and the significance of new drug discovery, the current study aimed to investigate whether carvacrol
administration can ameliorate PO-induced hyperuricemia. Our findings may contribute new insights for future research
on the prevention and treatment of hyperuricemia and gout.

Materials and Methods
Chemicals
Potassium oxonate (catalog# 156124), carvacrol (catalog# W224511) were purchased from Sigma-Aldrich (St. Louis,
MO, USA), while allopurinol was obtained from Pharmedic Laboratories (Pvt.) Ltd. (Lahore, Pakistan). The primary
antibodies TNF-α (SC-52B83) and nuclear factor-kappa B (p-NF-κB) (SC-271908) and other immunohistochemistryrelated consumables, including the Elite ABC kit (SC-2018) and 3,3-diaminobenzidine (DAB; SC-216567), were
procured from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The biotinylated secondary antibody (ab-6789) and
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DPX mounting media were purchased from Abcam (Cambridge, MA, USA). The enzyme-linked immunosorbent assay
(ELISA) kit for rat NLPR3 (CAS# A5652) was purchased from Shanghai MLBIO Biotechnology Co., Ltd. (Shanghai,
China), while the ELISA kit for rat TNF-α (Catalog# E-EL-R0019) was obtained from Elabscience (Houston, TX, USA).
The kits for uric acid, blood urea nitrogen, creatinine, and C-reactive protein (CRP) were purchased from Beckman
Coulter (Brea, CA, USA). All other consumables including formaldehyde, hydrogen peroxide (H2O2), reduced glutathione (GSH), glutathione S-transferase (GST), catalase, trichloroacetic acid, 1-chloro-2,4-dinitrobenzene (CDNB),
ethanol, xylene, and hematoxylin and eosin (H&E) stains were purchased from (Sigma-Aldrich).

Animals
Seventy healthy male adult Sprague-Dawley rats, weighing 200 ± 20 g and aged 8–12 weeks, were obtained from the
local breeding facility of the Riphah International University Islamabad, Pakistan, and randomly divided into five groups
(n=14 rats/group). The rats were placed in plastic cages and maintained at room temperature (18–22 °C), with a light and
dark cycle of 12 h. Throughout the experiment, the animals were fed with a rat pellet diet ad libitum and given free
access to tap water. All experimental protocols were approved by the Research and Ethics Committee (REC) of the
Riphah Institute of Pharmaceutical Sciences (RIPS), Riphah International University, Pakistan and by following guidelines of the Institute of Laboratory Animal Resources, Commission on Life Sciences University, National Research
Council (1996).

Induction of Hyperuricemia in Rats
Hyperuricemia was induced in rats as previously described.35 Briefly, the rats were intraperitoneally injected with
250 mg/kg PO, a urate oxidase inhibitor that promotes uric acid synthesis for seven consecutive days.36

Experimental Design and Drug Treatment
During the seven-day treatment, the experimental rats were divided into five groups and administered daily with 1%
dimethyl sulfoxide (DMSO) (saline group), 250 mg/kg PO (model group), 20 mg/kg (carvacrol 20 group), 50 mg/kg
(carvacrol 50 group), and 10 mg/kg allopurinol (allopurinol group). Carvacrol, allopurinol, and PO were dissolved in
normal saline containing 1% DMSO and were administered intraperitoneally (I/P). In all treatment groups, PO was
administered initially and then after 1 h either carvacrol or allopurinol was administered. The rats that successfully
passed the experimental period were further processed for experimentation. Four rats from the PO-treated group died
during the experiment; hence, new rats were added to compensate for the loss. Following the due period, the rats were
grouped into either the biochemical or histopathological cohorts (n = 7 per group) for sample collection and subsequent
analyses.

Blood and Tissue Sample Collection
First, the rats were subjected to 8 h fasting before blood collection. Second, on day 1 of treatment, blood samples were
collected via the tail vein to measure the baseline serum uric acid, urea, creatinine, and CRP levels. Third, after day 7 of
treatment, the rats were anesthetized, and blood samples were collected again via direct cardiac puncture using a 3-mL
BD syringe.37 Fourth, for serum biochemistry, blood (allowed to clot at 26 ± 2 °C) was collected in clotted tubes. Fifth,
the serum was extracted by centrifugation at 3000 rpm for 10 min. Finally, all rats were euthanized, and the tissue
samples were obtained.

Serum Biochemistry
The collected blood samples were used to estimate the serum biochemical parameters. Biochemical assays for determining serum urea, creatinine, uric acid, and CRP levels were performed using specific assay kits for each AU480
Biochemistry Analyzer (Beckman Coulter), following the manufacturer’s protocols.
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Histopathological Assessment of the Ankle–Knee Joint
The joint tissue samples were fixed with 4% paraformaldehyde and then decalcified using nitric oxide. After gross examination, the histological samples were embedded in paraffin blocks and cut into 4-μm-thin sections using a microtome38 for
subsequent analyses.

H& E Staining
H&E staining was performed following the methods described in previous studies.39,40 The tissue sections were
deparaffinized on coated slides using absolute xylene (100%) and rehydrated using ethyl alcohol series from 100% to
70%. After washing with distilled water, the slides were incubated in hematoxylin solution for 10 min (depending on the
nature of the hematoxylin stain). The hematoxylin stain was recycled, and the slides were placed under low-speed tap
water and subsequently dipped once for gentle treatment with 1% HCl and 1% ammonia water. The slides were incubated
with eosin and then air-dried. The dried slides were processed using a dehydration protocol and covered with glass
coverslips. Images were captured using an Olympus microscope (Olympus Co. Ltd., Tokyo, Japan), specifically checking
for aggregated inflammatory cells, degenerated muscle cells, and synovial fluid. The microscopic images were analyzed
using ImageJ software (NIH, Bethesda, MD, USA).41

Immunohistochemical Analysis
With slight modifications, immunohistochemical staining was performed as previously described.42 To retrieve the
antigen, the slides were subjected to proteinase K treatment and washed with PBS, and the peroxidase activity was
quenched. The slides were blocked with normal goat serum (NGS) and incubated overnight with mouse anti-nuclear
factor-κB (p-NF-κB) and mouse anti-TNF-α (1:100; Santa Cruz Biotechnology). After washing, the secondary antibodies
(1:50) were applied in a humidified chamber, followed by the ABC reagents (Santa Cruz Biotechnology). After washing,
the slides were stained with DAB and then mounted using DPX. ImageJ software (NIH) was used to quantitatively
evaluate the hyper-activated TNF-α and NF-κB. The total area was calculated by optimizing the TNF-α and NF-κB
threshold intensity in the positive cells.

Oxidative Enzymes Analysis
Stress markers glutathione (GSH) and glutathione s-transferase (GST) are generally used to measure oxidative
damage and the relative effect of the test compounds. Phenylmethylsulfonyl fluoride (PMSF) was applied to freshly
cut and homogenized (0.1M PBS at pH 7.4) brain tissue samples and centrifuged (4000 X g) at 4 °C for 10 minutes.
The supernatant layer was collected to evaluate the GSH levels using the already reported method with little
modifications. To dissolve 0.6 mM DTNB, 0.2 M of sodium phosphate solution was used and 2 mL of this
subsequent mixture was added to 0.2 mL of already collected supernatant. In order to collect a 3 mL solution,
the final volume makeup was done with 0.2 M PBS. After 10 min, the absorbance of the test mixture was
determined at a wavelength of 412 nm. As a negative and positive control, the phosphate buffer and DTNB solution
were used respectively, which were further used to correct the measured absorbance. The results obtained were
expressed in µmoles/mg of proteins. Glutathione s-transferase (GST) marker levels have also been determined using
a previously documented protocol with little modifications.43 To prepare a test solution containing 5 mM GSH and 1
mM CDNB, a freshly prepared 0.1 M PBS was used. In a glass vial containing 1.2 mL of test solution in triplicate,
60 μL of the already separated supernatant layer was added. Water was also used to prepare blanks in triplicate in
the same proportion. These prepared solutions (210 μL) were added to the microtiter plate and the ELISA
microplate reader was used to detect the absorbance (ʎmax = 340 nm, 5 min at 23°C). Likewise, the values
obtained were expressed in μmoles/mg of proteins. Catalase (CAT) is a common heme-containing enzyme that
catalyzes the decomposition of H2O2 to H2O. Catalase activity was measured by monitoring the decrease in
absorbance due to decomposition of H2O2 at 240 nm according to the previously reported method with minor
modifications.44 A reaction mixture consisting of 1.95 mL of PBS (pH 7.0), 1mL of hydrogen peroxide (H2O2), and
0.05mL of supernatant was prepared and the absorbance was measured at 240 nm. The results were expressed as
µmoles of H2O2/min/mg of protein.
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Assessment of LPO in the Joint Tissues
A previously published method was used to evaluate LPO.44 The rat joint tissue was homogenized in 20 mM Tris-HCl
using a polytron homogenizer. Following supernatant collection, ferrous ammonium sulfate was added to the clear
supernatant, and the mixture was incubated at 37 °C to calculate LPO. Subsequently, 2-thiobarbituric acid (TBA) was
added to the mixture, and the absorbance was calculated at 532 nm using a microplate reader.

ELISA
The levels of NLPR3 and TNF-α in the joint tissues were determined using the rat NLPR3 and TNF-α ELISA kits,
following the manufacturers’ instructions. The samples were homogenized in PBS at 15,000 RPM, and the supernatant
was collected. The total protein concentration was quantified using the BCA method (Elabscience), while the concentrations of NLPR3 and TNF-α were measured using the ELx808 ELISA microplate reader (Bio-Tek Instruments, Winooski,
VT, USA). The concentrations (pg/mL) were subsequently normalized to the total protein content (pg/mg).

Statistical Analysis
The data were expressed as means ± standard error of the mean (SEM) and analyzed via one-way analysis of variance
(ANOVA), followed by Tukey’s post-hoc test, using GraphPad Prism software (GraphPad, San Diego, CA, USA).
Statistical significance was set at p < 0.05. The symbol # shows a significant difference relative to the saline group, and *
shows a significant difference relative to the PO group.

Results
Effects of Carvacrol Treatment on the Serum Biochemistry Profile of Hyperuricemic
Rats
The effects of daily intraperitoneal administration of carvacrol for seven consecutive days in normal and PO-induced
hyperuricemic rats are presented in Table 1. Compared to the normal group, the model group exhibited significantly
increased serum uric acid and CRP levels (p < 0.001), indicating the successful induction of hyperuricemia in rats.45
A comparison between hyperuricemia and allopurinol-treated rats also showed a significant decrease in the serum uric
acid and CRP levels (p < 0.001). The groups treated with different doses of carvacrol (20 and 50 mg/kg) presented
similar results (p < 0.001), but a slightly pronounced effect was observed on the serum uric acid level of the carvacrol 50
group. The anti-inflammatory effect of carvacrol was also observed in both groups, as evidenced by the reduced serum
CRP levels. In addition, to assess the relative safety of carvacrol treatments on the rat kidneys, we measured the serum
creatinine levels and found no renal impairment at the utilized dosages.
Table 1 Effects of Carvacrol and Allopurinol Treatments (n = 7 per Group) on the Serum Levels of Urea, Creatinine, Uric Acid, and
CRP in PO-Induced Hyperuricemic Rats
Treatment

Urea (mg/dl)

Creatinine (mg/dl)

Uric Acid (mg/dl)

CRP (mg/L)

Baseline

25.86 ± 0.79

0.276 ± 0.03

2.83 ± 0.04

1.17 ± 0.11

Saline

26.40 ± 0.87

0.29 ± 0.04

2.91 ± 0.053

1.3 ± 0.1

PO model 250mg/kg

32.0 ± 0.9##

0.379 ± 0.02##

7.19 ± 0.33###

28.6 ± 1.52###

Allopurinol 10mg/kg

28.67 ± 0.88

0.303 ± 0.008

2.53 ± 0.29***

1.63 ± 0.12***

Carvacrol 20

20.75 ± 0.48***

0.305 ± 0.04

2.43 ± 0.11***

1.77 ± 0.15***

Carvacrol 50

19.75 ± 0.63***

0.33 ± 0.04

2.01 ± 0.57***

1.75 ± 0.15***

Notes: PO (250 mg/kg) was administered to induce gout in the model group. Saline-treated rats were considered as the control group, while allopurinol-treated rats were
used as the standard group. The data are presented as means ± SEM. ###p < 0.001 and ##p < 0.01 vs saline group, ***p < 0.001 vs model group. Mean values with dissimilar
superscripts in a column significantly vary at p < 0.05.
Abbreviations: CRP, C-reactive protein; PO, potassium oxonate.
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Carvacrol Treatment Ameliorates Renal and Joint Degeneration in Hyperuricemic
Rats
Compared to the saline group, which showed no pathological changes and normal architecture of the joint tissues,
significant alterations were observed in the PO group, including large pale areas with giant cells and abundant MSU
crystals in both the intracellular and extracellular spaces, indicating the presence of gout (Figure 1, Table 2).
Furthermore, a moderate amount of inflammatory cells, which can lead to inflammation and edema formation, were
observed in the carvacrol 20 group. Notably, there were no inflammatory cells, MSU crystals, spared skin, and muscle
cells in the carvacrol 50 group, indicating normal architecture of the joint tissues. In contrast, a small number of
inflammatory cells was observed in the allopurinol group, but there were no MSU crystals in the intracellular and
extracellular spaces. The renal function test revealed no significant cellular changes, thus validating the safety and nonhazardous effect of carvacrol treatment on rat kidneys.

Carvacrol Treatment Reduces the Levels of Inflammatory Cytokines in Hyperuricemic
Rats
The concentration of NLRP3 in the tissues surrounding the rat knee joints was determined using ELISA. Compared
to the baseline expression (day 1 of treatment), the level of NLRP3 at day 7 was significantly enhanced in the model
group (p < 0.01, Figure 2A). In contrast, the NLRP3 levels in the allopurinol- and carvacrol-treated groups (20 and
50 mg/kg) were significantly reduced at day 7 (p < 0.05). Since NLRP3 is associated with downstream inflammatory
cytokines, we also investigated the effects of carvacrol treatment on the TNF-α and p-NFκB levels. Notably, we
observed that the level of TNF-α was significantly higher in the model group than in the saline group (p < 0.001,
Figure 2B). However, the carvacrol treatment attenuated the PO-induced increase in TNF-α level in hyperuricemic
rats. For validation, we performed immunohistochemical analysis and observed similar results (Figure 2C). We also
performed immunohistochemistry for p-NFκB and found that carvacrol attenuated the p-NFκB level in the model
group (p < 0.001, Figure 2D).

Effects of Carvacrol Treatment on the Levels of Oxidative Stress Mediators in
Hyperuricemic Rats
As early indicators of oxidative damage, the levels of enzymatic and non-enzymatic oxidants, namely GST and GSH, were
measured in the joint tissues. The administration of PO-induced ROS coincided with the exhaustion of GSH and GST in the
joint tissue homogenates of the model group (Figure 3A and B). In contrast, treatment with carvacrol (20 and 50 mg/kg)
resulted in increased GSH and GST levels and restored CAT levels in the joint tissue homogenates (Figure 3C). The
oxidative stress and ROS generated in hyperuricemia generally induce the formation of several detrimental products (eg,
malondialdehyde) that can be measured using the thiobarbituric acid reactive substances (TBARS) assay. The LPO assay

Figure 1 Effects of carvacrol treatment on the morphological integrity of the joint tissues in PO-induced hyperuricemic rats. The joint tissues (n = 7 per group) were stained
with H&E and then observed under 10× magnification. Scale bar = 50 µm. Saline group: 1, skin tissue; 2a and 2b, synovial fluid, 3, muscle tissue. Model group (PO treatment):
1 indicates muscle; 2 indicates skin; 3 indicates urate crystals. Blue arrows indicate inflammatory cells. Allopurinol group (10 mg/kg allopurinol treatment): 1 indicates
inflammatory plasma cells (lymphocytes); 2 indicates synovial fluid; 3 indicates muscle cell. Carvacrol 20 group (20 mg/kg carvacrol treatment): 1a and 1b are moderate
inflammation (acute and chronic); 2 indicates skin; 3 indicates muscle. Carvacrol 50 group (50 mg/kg carvacrol treatment): 1 indicates muscle; 2 indicates skin; 3 indicates
inflammatory cells (encircled).
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Table 2 Effects of Carvacrol Treatment on the Inflammatory Mediators of PO-Induced Hyperuricemic Rats
Groups

MSUC

Inflammatory Cells-

Synovial Fluid

Skin/Muscle

(Shown by Blue

Lymphocytes (Shown by Blue

(Shown by Red

(Shown by Red

Arrows)

Arrows)

Arrows)

Arrows)

Saline

0

0

1

1

PO model 250mg/kg

3

2

0

1

Allopurinol 10mg/kg

2

1

1

1

Carvacrol 20mg

0

1

1

1

Carvacrol 50mg

0

0

1

1

Notes: 0 indicates absence; 1 indicates presence; 2 indicates >10 particles per field; 3 indicates >20 particles per field.

revealed that compared to the saline group, there was an increase in the levels of LPO products in the model group,
suggesting a high degree of LPO-induced damage in the joint tissue (Figure 3D). Notably, treatment with carvacrol and
allopurinol both reduced the LPO-induced damages in the joint tissues of hyperuricemic rats.

Discussion
In the present study, we investigated the effects of carvacrol on the oxidative and inflammatory cascades of hyperuricemic rats and obtained results corroborating those of previous studies.46,47 We further evaluated the positive effects of
carvacrol treatment and observed a dose-dependent response in the carvacrol-treated groups, with results comparable to
those of allopurinol-treated rats. Natural drugs, such as carvacrol, are extensively investigated for their great pharmacological potential against various diseases, specifically for elucidating the underlying disease pathology and developing
newer and safer therapeutic alternatives. Notably, previous studies discovered that carvacrol is a dietary adjuvant that can
ameliorate gout-like symptoms.48,49 Here, we successfully induced hyperuricemia in rats using PO, which was validated

Figure 2 Effects of carvacrol treatment on the inflammatory mediators of PO-induced hyperuricemic rats. The tissue levels of (A) NLRP3 and (B) TNF-α were quantified
using ELISA (n = 7 per group). The data are presented as means ± SEM. Representative images showing the immunoreactivity of (C) TNF-α (D) p-NF-κB (n = 7 per group).
Scale bar = 50 μm, 40× magnification. The data are presented as means ± SEM. ***p < 0.001 compared to the model group (PO treated), ###p < 0.001 compared to the
saline group, ##p < 0.01 compared to the saline group, *p < 0.05 compared to the model group (PO treated).
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Figure 3 Effects of carvacrol and allopurinol treatments on the enzymatic and non-enzymatic oxidants of PO-induced hyperuricemic rats. The enzymatic activities of (A)
GSH, (B) GST, (C) CAT, and (D) LPO were measured. The data are presented as means ± SEM. ###p < 0.001 compared to the saline group, ***p < 0.001 compared to the
model group (PO-treated), **p < 0.01 compared to the model group (PO-treated).
Abbreviations: PO, potassium oxonate; CAT, catalase; GSH, reduced glutathione; GST, glutathione-S-transferase; LPO, lipid peroxidation.

by the high serum uric acid and CRP levels.45 We also found that carvacrol treatment attenuated the levels of both serum
CRP and TNF-α in the joint tissues of hyperuricemic rats.
Several studies suggested that the hyperactivity of xanthine oxidase is a contributing factor of hyperuricemia that
triggers uric acid overproduction, which is mainly concentrated in the limbs.50 Moreover, the early phase of
inflammation starts with immune cell infiltration into the gouty tissue, inducing the release of inflammatory
cytokines (eg, IL-1β, IL-6, and TNF-α).15,19 This subsequently exacerbates the inflammatory reactions and leads
to tissue destruction.51,52 In addition, the deposition of MSU crystals in the joint tissue reportedly aggravates the
pathological cascade of gout by activating the NLRP3 inflammasome,53 which modulates the release of inflammatory mediators and cytokines (eg, COX2 and p-NF-κB), thus further aggravating the pathological cascade. We also
investigated the role of the NLRP3 inflammasome and its mediators and discovered that the inflammation-related
markers can exacerbate pathogenicity in the model group, while carvacrol treatment reduced the levels of both MSU
crystals and inflammatory mediators. However, the exact mechanism underlying the anti-inflammatory effects of
carvacrol requires further research. Notably, our findings corroborate previous observations,54,55 wherein targeting
the NLRP3 inflammasome can modulate MSU crystal deposition. Moreover, enhanced neutrophil permeation into
the intraarticular and periarticular spaces during gout can induce severe pain due to edema and erythema
formation.56 Furthermore, dysfunction in the NLRP3 assembly impairs the neutrophil influx into the gouty tissue,
suggesting the critical involvement of NLRP3 in gouty arthritis.57 Additionally, Β-hydroxybutyrate prevents NLRP3
inflammasome activation and MSU crystal deposition by downregulating NLRP3 expression.55 Recent studies have
identified several therapeutic targets, including chemokines, TNF-α, and NLPR3 inflammasomes, and correspondingly developed different anti-inflammatory strategies against gout.58,59 Therefore, directly targeting NLRP3 and its
associated factors or proteins may effectively inhibit NLRP3 activation and potentially produce benefits in gout
treatment.60 Previous clinical trials utilizing different drugs that target only a single step in a specific disorder have
failed. However, in this study, carvacrol ameliorated the detrimental effects of hyperuricemia by targeting multiple
stages, including inflammation, oxidative stress, and cellular degeneration. Hence, our results demonstrate that
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a natural drug with protective effects that can act against different stages of pathogenesis may be more effective for
clinical applications.
The use of urate-lowering agents are often associated with renal injuries, thus limiting their applications in renalcompromised patients.61 Here, we demonstrate the renal safety of carvacrol that was not previously observed with other
natural compounds, such as polydatin, which decreases the serum uric acid level but increases the serum creatinine level,
thereby indicating abnormal metabolic status in hyperuricemic rats.62 In addition, carvacrol exhibited a relative safety
profile because no impairment was observed in the kidneys. The serum creatinine and urea levels were also normal and
similar to previous findings.63 Serum uric acid reportedly accumulates in the peripheral joints as MSU crystals. However,
the crystals spontaneously dissolve when uric acid concentrations fall below the saturation level of MSU crystals, and
thus, gout can be resolved.7 Here, the carvacrol treatment effectively reduced the serum uric acid level, as confirmed by
the low number of crystal aggregates observed during morphological analysis.
Since inflammation is a key factor in gout pathogenesis, compounds exhibiting both anti-hyperuricemic and antiinflammatory activities are essential for developing treatment strategies for gout.64 However, currently available
medications exert considerable anti-hyperuricemic effects but have poor anti-inflammatory potential. Notably, our
histopathological findings revealed that different doses of carvacrol can inhibit the accumulation of inflammatory cells
in both the connective and muscle tissues, thereby confirming its effective anti-inflammatory activity. Overall, our
findings suggest that carvacrol has great therapeutic potential because the significant decrease in serum uric acid level
was accompanied by reduced inflammation in the joint tissues, and these effects did not produce toxicity to the rat
kidneys.

Conclusions
Taken together, we can conclude from our results that carvacrol possesses antioxidant and anti-inflammatory properties
and ameliorated the gout symptoms in hyperuricemic rats in a dose-dependent manner. Further, our proposed mechanism
suggests that carvacrol activated the endogenous antioxidant proteins like GSH, GST, and catalase coupled to the
downregulation of anti-inflammatory proteins like p-NFκB and NLRP3 (Figure 4). Collectively, these protective properties of carvacrol may offer a new therapeutic option for protecting the joint tissues from inflammation and oxidative
stress-induced degeneration.

Figure 4 Diagrammatic illustration elaborating the underlying antioxidant and neuroprotective potential of carvacrol in a PO-induced gout model.
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